Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets

50Citations
Citations of this article
114Readers
Mendeley users who have this article in their library.

Abstract

Background: Neuroimaging studies have used magnetic resonance imaging-derived methods to assess brain volume loss in multiple sclerosis (MS) as a reliable measure of diffuse tissue damage. Methods: In the CLARITY study (ClinicalTrials.gov NCT00213135), the effect of 2 years’ treatment with cladribine tablets on annualized percentage brain volume change (PBVC/y) was evaluated in patients with relapsing MS (RMS). Results: Compared with placebo (–0.70% ± 0.79), PBVC/y was reduced in patients treated with cladribine tablets 3.5 mg/kg (–0.56% ± 0.68, p = 0.010) and 5.25 mg/kg (–0.57% ± 0.72, p = 0.019). After adjusting for treatment group, PBVC/y showed a significant correlation with the cumulative probability of disability progression (HR = 0.67, 95% CI = 0.571, 0.787; p < 0.001), with patients with lower PBVC/y showing the highest probability of remaining free from disability progression at 2 years and vice versa. Conclusions: Cladribine tablets given annually for 2 years in short-duration courses in patients with RMS in the CLARITY study significantly reduced brain atrophy in comparison with placebo treatment, with residual rates in treated patients being close to the physiological rates.

References Powered by Scopus

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

13502Citations
N/AReaders
Get full text

Accurate, robust, and automated longitudinal and cross-sectional brain change analysis

1763Citations
N/AReaders
Get full text

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

810Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Treatment of multiple sclerosis — success from bench to bedside

239Citations
N/AReaders
Get full text

MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice

188Citations
N/AReaders
Get full text

B cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies

152Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

De Stefano, N., Giorgio, A., Battaglini, M., De Leucio, A., Hicking, C., Dangond, F., … Sormani, M. P. (2018). Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Multiple Sclerosis, 24(2), 222–226. https://doi.org/10.1177/1352458517690269

Readers over time

‘17‘18‘19‘20‘21‘22‘23‘24‘2509182736

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 32

52%

Researcher 17

28%

Professor / Associate Prof. 10

16%

Lecturer / Post doc 2

3%

Readers' Discipline

Tooltip

Medicine and Dentistry 35

58%

Neuroscience 17

28%

Pharmacology, Toxicology and Pharmaceut... 4

7%

Biochemistry, Genetics and Molecular Bi... 4

7%

Article Metrics

Tooltip
Mentions
Blog Mentions: 2
News Mentions: 2
References: 2

Save time finding and organizing research with Mendeley

Sign up for free
0